Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma by Ghazal Tansir, Sameer Rastogi, Shamim Ahmed Shamim, Adarsh Barwad

Subjects: Get full text

Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 studyResearch in contex... by Junning Cao, Guangliang Chen, Lihua Qiu, Liling Zhang, Ming Jiang, Ying Cheng, Qiaohua Zhang, Lihong Liu, Ping Li, Yuerong Shuang, Huaqing Wang, Hongwei Xue, Huijing Wu, Meifang Zheng, Keshu Zhou, Zhiming Li, Hongmei Jing, Wei Yang, Zunmin Zhu, Wenyu Li, Jiaxuan Wangwu, Heyu Huang, Qiantao Jia, Dongmei Chen, Songhua Fan, M. Ming Shi, Weiguo Su

Subjects: Get full text

A novel therapeutic strategy for osteosarcoma using anti-GD2 ADC and EZH2 inhibitor by Jing Shan, Zicheng Lin, Harunor Rashid, Peng Huang, Lei Qiang, Yihao Liu, Guanlu Shen, Yuchen Li, Jiaming Cui, Zhi Su, Hanbo Wang, Bixuan Cao, Cheng Zhou, Veysel Kayser, Bo Ning

Subjects: Get full text